Trial Profile
A Phase 2 Study of Vorinostat (NSC 701852) in Metastatic Uveal Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 17 Feb 2023
Price :
$35
*
At a glance
- Drugs Vorinostat (Primary)
- Indications Uveal melanoma
- Focus Therapeutic Use
- 15 Feb 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 15 Feb 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2023.
- 29 Dec 2021 Planned primary completion date changed from 30 Jun 2022 to 31 Dec 2022.